Zacks upgraded Integra LifeSciences, a health technology firm, from a "sell" rating to a "hold" rating, according to Dakota Financial News.
Here are four notes:
1. Integra's second quarter 2015 results surpassed the Zacks Consensus Estimate.
2. The company's shares traded down 1.32 percent on Mon., Sept. 14.
3. The stock has a 50-day moving average of $62.04 and a 200-day moving average of $59.39.
4. The company has a market cap of $2.10 billion and a P/E ratio of 52.105.
More articles on orthopedics:
Dr. Jeremy Wells joins Hattiesburg Clinic: 3 notes
Fox Valley Orthopedics' Dr. Vishal Mehta pioneers new knee surgery technique: 4 things to know
Orthopedic surgeon to know: Dr. Mark A. Frankle of Florida Orthopaedic Institute